Search
Ebvaciclib
go.drugbank.com/drugs/DB18967InvestigationalEbvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).
Mosliciguat
go.drugbank.com/drugs/DB19425InvestigationalMosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. … Newer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200].
Categories: Dopamine D2 Receptor AgonistsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.
Categories: Corticotropin-releasing Factor Type 1 Receptor Antagonist, Cytochrome P-450 SubstratesNedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigationalNedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formati...
Padimate O
go.drugbank.com/drugs/DB11570ApprovedPadimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent ph...
Mixtures: Native Tan Sun Protection Lotion SPF 8, Native Tan Sun Protection Lotion SPF 15Products: Native Tan Regular Tanning Oil SPF 4, Native Tan Dark Tanning Lotion SPF 4Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalPharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease … In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function.
Categories: Angiotensin 2 Receptor Blocker, Angiotensin Receptor Antagonistsanti-OX40 antibody BMS 986178
go.drugbank.com/drugs/DB15773InvestigationalA macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.
PF-03654764
go.drugbank.com/drugs/DB12360InvestigationalPF-03654764 has been used in trials studying the basic science and treatment of Allergic Rhinitis.